This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.
Last month the BMJ announced a new policy on sharing data from clinical trials. From January 2013, trials of drugs and medical devices will be considered for publication only if the authors commit to making the relevant anonymised patient level data available on reasonable request. This new policy will apply to any paper that reports the main endpoints of a randomised controlled trial of one or more drugs or medical devices in current use, whether or not the trial was funded by industry (box).
Why the new policy? Because it is no longer possible to pretend that a report of a clinical trial in a medical journal is enough to allow full independent scrutiny of the results. Journals are, of course, not the only potential channel for such scrutiny, but as long as publication remains the main currency for academic recognition, journals have a responsibility to use what power they have to push for greater transparency. If research is to help doctors and patients make the best clinical decisions, it must be reliable and reproducible, but these are qualities that current peer review processes cannot assure.
Link to access full article: http://www.bmj.com/content/345/bmj.e7888